T
Torus Biosystems
Infectious Disease Diagnostics qPCR | Torus Biosystems
About Torus Biosystems
Torus Biosystems is a pioneering company in the field of infectious disease diagnostics and DNA/RNA analysis. The company is revolutionizing the way infectious diseases are diagnosed by integrating advanced microarray and qPCR (quantitative Polymerase Chain Reaction) technologies. These technologies allow for the rapid and accurate analysis of genetic material, providing comprehensive insights that are crucial for clinical decision-making and medical innovation.
Read full description
Torus Biosystems serves a diverse range of clients, primarily in the healthcare sector. This includes hospitals, clinical laboratories, and research institutions that require precise and timely diagnostic information to manage and treat infectious diseases. The company operates in the rapidly growing market of molecular diagnostics, which is becoming increasingly important due to the rise of antibiotic-resistant bacteria and emerging superbugs.
The business model of Torus Biosystems is centered around its proprietary platform, Synestia. This platform delivers highly multiplexed data, meaning it can analyze multiple genetic targets simultaneously, and places this data into context to guide clinical interventions. By providing actionable insights quickly, Synestia helps healthcare providers make informed decisions, ultimately improving patient outcomes.
Torus Biosystems generates revenue through the sale of its diagnostic platforms and related consumables. Additionally, the company may offer subscription-based services for ongoing data analysis and support, ensuring that clients have continuous access to the latest diagnostic insights.
In summary, Torus Biosystems is at the forefront of infectious disease diagnostics, leveraging cutting-edge technology to provide critical insights that drive clinical and medical advancements.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Brookline, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 59.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Torus Biosystems.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2021 | $25M | $100M | David R. Walt · Northpond Ventures | — |
| EARLY VC✓Equity / VC | Jan 2020 | $1.5M | $6M | Undisclosed | — |
Growth signals
Latest recorded traffic for Torus Biosystems is 880 monthly website visits, up 238.5% over the last three months. Torus Biosystems's team declined 40% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Northpond Ventures
David R. Walt
Other known investors2 additional known investors
Harvard University
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Torus Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Torus Biosystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.